Literature DB >> 3215524

Mulcos: a vector for amplification and simultaneous expression of two foreign genes in mammalian cells.

H Ikeda1, J Trowsdale, I Saito.   

Abstract

A method was developed for amplification and expression of foreign genes in mammalian cells. This procedure exploits the fact that an SfiI cleavage site, GGCCGCCT/CGGCC (the recognition sequences are underlined), is present at the SV40 replication origin and the cleaved ends, CCT-3' and AGG-3', are not rotationally equivalent. Thus DNA fragments flanked by the SfiI sites can be ligated in head-to-tail tandem arrays and cloned in cosmids; the resulting construct is called a mulcos. The cosmid vector we have used, pCHD2L, contains the single SfiI site as well as HmBR and dhfr genes, selectable markers in mammalian cells. Cassette plasmid pmoRH contains two expression units, each of which consists of SV40 early promoter, EcoRI or HindIII cloning site, small T splicing region, and poly(A) signal, and the two units as a whole are flanked by the SfiI sites. A set of alpha- and beta-chain cDNAs of a human major histocompatibility class-II antigen were inserted into the EcoRI and HindIII sites, respectively. The purified SfiI fragment, containing both expression units, was then ligated with SfiI-linearized cosmid vector pCHD2L at a molar ratio of 20:1. A mulcos containing eight pairs of the alpha- and beta-chain expression units was isolated by in vitro packaging in phage lambda heads and subsequent transfection into Escherichia coli. Drug-selected cells transfected with the mulcos contained significantly higher copy numbers of the expression units and higher expression levels than those obtained using conventional plasmids. More than 85% of these cells expressed class-II antigen on their cell surfaces.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3215524     DOI: 10.1016/0378-1119(88)90073-x

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  8 in total

1.  LCR/MEL: a versatile system for high-level expression of heterologous proteins in erythroid cells.

Authors:  M Needham; C Gooding; K Hudson; M Antoniou; F Grosveld; M Hollis
Journal:  Nucleic Acids Res       Date:  1992-03-11       Impact factor: 16.971

2.  Fine mapping of HLA class II monoclonal antibody specificities using transfected L cells.

Authors:  D M Altmann; J M Heyes; H Ikeda; A M Sadler; D Wilkinson; J A Madrigal; J G Bodmer; J Trowsdale
Journal:  Immunogenetics       Date:  1990       Impact factor: 2.846

Review 3.  Analysis of antigen presentation using HLA transfectants.

Authors:  D M Altmann; D Wilkinson; H Ikeda; J Trowsdale
Journal:  Immunol Res       Date:  1990       Impact factor: 2.829

4.  Possible role of splice acceptor site in expression of unspliced gag-containing message of Moloney murine leukemia virus.

Authors:  M Oshima; T Odawara; T Matano; H Sakahira; Y Kuchino; A Iwamoto; H Yoshikura
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

5.  Two species of human CRK cDNA encode proteins with distinct biological activities.

Authors:  M Matsuda; S Tanaka; S Nagata; A Kojima; T Kurata; M Shibuya
Journal:  Mol Cell Biol       Date:  1992-08       Impact factor: 4.272

6.  Multicycle infection of hepatitis C virus in cell culture and inhibition by alpha and beta interferons.

Authors:  Y K Shimizu; H Yoshikura
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

7.  Experimental autoimmune panencephalitis and uveoretinitis transferred to the Lewis rat by T lymphocytes specific for the S100 beta molecule, a calcium binding protein of astroglia.

Authors:  K Kojima; T Berger; H Lassmann; D Hinze-Selch; Y Zhang; J Gehrmann; K Reske; H Wekerle; C Linington
Journal:  J Exp Med       Date:  1994-09-01       Impact factor: 14.307

8.  Growth dependence of human papillomavirus 16 DNA-positive cervical cancer cell lines and human papillomavirus 16-transformed human and rat cells on the viral oncoproteins.

Authors:  S Watanabe; T Kanda; K Yoshiike
Journal:  Jpn J Cancer Res       Date:  1993-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.